Amgen and QB3@953 announce winners of The Amgen Golden Ticket
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) and QB3@953 today announced that Darmiyan and Enable Biosciences have won the Amgen Golden Ticket at QB3@953. Each company receives one year of lab space at the QB3@953 life sciences incubator, additional facility benefits and connections to Amgen's scientific and business leaders to help advance their scientific programs.
Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that data from HAVEN 1, a phase III study evaluating once-weekly subcutaneous emicizumab prophylaxis (preventative) in adults and adolescents with haemophilia A with inhibitors, were published in The New England Journal of Medicine (NEJM).
BESPONSA® approved in the EU for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) announced that the European Commission has approved BESPONSA® (inotuzumab ozogamicin) as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). This indication includes treatment of adults with Philadelphia chromosome positive (Ph+) as well as Philadelphia chromosome negative (Ph-) relapsed or refractory B-cell precursor ALL.
Jardiance® (empagliflozin) analysis reinforces established safety profile
- Details
- Category: Boehringer Ingelheim
An analysis of pooled safety data from 15 studies plus 4 extension studies involving more than 12,500 adults with type 2 diabetes demonstrated treatment with Jardiance® (empagliflozin) tablets (10 mg or 25 mg) was well tolerated, with no imbalance in lower limb amputations or bone fractures compared with placebo. The analysis, which includes the EMPA-REG OUTCOME® trial, was published this month in Advances in Therapy.(1)
Merck awards €1.25 million to research projects through its 2017 Grant for Fertility Innovation (GFI)
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced its commitment to award €1.25 million to research projects in the field of fertility, supporting the advancement of medical science through the Grant for Fertility Innovation (GFI) in 2017. Launched as the first of the Merck Grants for Innovation in 2009, Merck's GFI is providing encouragement for innovation and support for scientists to realize projects that could potentially lead to the next breakthrough in the fertility treatment area.
Roche acquires mySugr to form a leading open platform for digital diabetes management
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) and mySugr have signed an agreement under which Roche acquired all shares of mySugr GmbH. Counting more than one million users globally, mySugr is one of the leading mobile diabetes platforms in the market and will become an integral part of Roche's new patient-centered digital health services platform in diabetes care.
'More than Systemic Sclerosis: The Inside Story' - patients reveal the unseen impact of lung fibrosis
- Details
- Category: Boehringer Ingelheim
'More than Systemic Sclerosis: The Inside Story' launches today to mark World Scleroderma Day. This global initiative highlights the importance of understanding the 'inside story' of each individual living with systemic sclerosis, and to increase awareness of the potential serious consequences when fibrosis develops in vital organs such as the lungs.
More Pharma News ...
- Pfizer breaks ground on new R&D facility in Chesterfield, Missouri
- FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
- Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
- Merck Foundation established
- The made-in-Italy fast-track acceleration program dedicated to projects in life science
- Merck Ventures creates new immuno-oncology company iOnctura
- New patient survey highlights need for more action to help severe asthma patients gain control of their disease